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Abstract
Objectives: The aim of this study was to evaluate the very long-term clinical outcome
after radioactive stent (RS) implantation and intracoronary β radiation brachyther-
apy (IRBT).
Background: Radioactive stents (RS) and intracoronary β radiation brachytherapy
(IRBT) were introduced to prevent restenosis after percutaneous coronary interven-
tion (PCI). Both techniques were associated with a higher incidence of major adverse
cardiac events (MACE) in the short and intermediate-term follow up as compared to
conventional PCI.
Methods: One hundred and thirty-three patients received radioactive stents (32P)
and 301 patients were treated with IRBT adjunctive to PCI. These groups were pro-
pensity matched to respectively 266 and 602 control patients who were treated with
routine PCI during the same inclusion period. Endpoints were all-cause mortality and
MACE, defined as all-cause death, any myocardial infarction or any revascularization.
Results:Median follow-up duration was 17 years. All-cause mortality rates were sim-
ilar in all groups. Adjusted hazard ratios for MACE and mortality in the RS cohort
were 1.55 (95% CI 1.20–2.00) and 0.92 (95% CI 0.63–1.34), respectively. Adjusted
hazard ratios for MACE and all-cause mortality in the IRBT cohort were 1.41 (95% CI
1.18–1.67) and 0.95 (95% CI 0.74–1.21), respectively. The difference in MACE rates
was predominantly driven by coronary revascularizations in both groups, with a
higher MI rate in the IRBT group as well.
Conclusions: Coronary radiation therapy was associated with early increased MACE
rates, but the difference in MACE rates decreased beyond 2 years, resulting in a com-
parable long-term clinical outcome. Importantly, no excess in mortality was observed.
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1 | INTRODUCTION
Despite widespread use of percutaneous coronary intervention (PCI),
even today restenosis remains a limitation of PCI, and it was even more
so in the past.1–4 Restenosis after stent implantation is thought to be the
result of neointimal proliferation, while restenosis after coronary angio-
plasty and atherectomy is mainly caused by vessel wall remodeling.5–7
Over the past decades, multiple solutions have been suggested to pre-
vent the occurrence of restenosis. Around the year 2000, intracoronary
radiation therapy, also referred to as coronary brachytherapy, was intro-
duced as a potential solution to restenosis using several isotopes with
different radiation particles. The underlying rationale was that radiation
is a potent inhibitor of cellular proliferation. Rather disappointing short-
and mid-term clinical results together with a high demand on logistical
and radiation safety aspects on one hand and the promising early results
of drug eluting stents that were introduced soon after and, which were
much easier to handle in the catheterization laboratory on the other
hand, led to a rapid decline of intracoronary brachytherapy which was, at
that time, then widely perceived as “treatment failure.”8–11 This failure
was mainly caused by the occurrence of restenosis at the extremities of
the irradiated coronary segment, a phenomenon described in the past as
“edge effect,” typically caused by “geographic miss.”
Geographic miss refers to an anatomical mismatch between the
coronary segment that has been injured by dilation and/or implanta-
tion balloons and the segment that has received full-dose irradiation.
Injured coronary segments, receiving low-dose radiation due to sub-
optimal position of the radiation source have been demonstrated to
cause restenosis, typically at the edges of the irradiated lesions.12–14
However, there is paucity of data when it comes to the long run
after coronary radiation therapy. The aim of this study is to evaluate
the long-term (17 years) clinical outcome after radioactive stent
implantation (32P β-emitting radioactive stents [RS]) and intracoronary
β radiation brachytherapy (IRBT) in comparison to matched control
groups.
2 | MATERIALS AND METHODS
2.1 | Patient population
Our study was an observational, longitudinal, matched (propensity
score 1:2) single-center study of 434 radiation therapy patients and
868 control patients. Between November 1997 and July 2000,
133 patients received one or two radioactive stents and between
April 1997 and December 2002, 301 patients were treated with
intracoronary β radiation brachytherapy adjunctive to PCI at the Eras-
mus University Medical Center in Rotterdam, the Netherlands.15,16
The patients in the radioactive stent group were part of five different
studies, previously reported. Briefly, the IRIS 1 study was a safety and
feasibility study and IRIS 2 was a European dose finding study.8,17 The
cold end, the hot end and the square-shouldered balloons were stud-
ies with dedicated RS and balloons to overcome the problem of edge
stent restenosis observed with this therapeutic modality.18,19
To evaluate radiation therapy related outcomes, each of the two
radiation groups was compared with control patients who were
treated with standard routine PCI during the same inclusion period. In
the same time span, a total of 5,224 patients were treated with bare
metal stents, balloon angioplasty or atherectomy in our institution.
For selecting a representative control group, propensity score meth-
odology was used to match the 133 radioactive stent patients with
266 control patients and the 301 IRBT patients with 602 control
patients.
Informed, written consent was retrieved for all radiation therapy
patients. For the patients in the control group, approval was retrieved
from the Medical Ethical Committee (METC-2013-262).
PCI, radiation therapy and concomitant medication were
described in detail previously.10–12 Antiplatelet therapy after RS
implantation consisted of either aspirin 80 mg daily indefinitely and
ticlopidine 250 mg BID or clopidogrel 75 mg daily for one to 6 months
according to the study, while all BMS (bare metal stent) patients
received aspirin 80 mg daily and ticlopidine 250 mg BID or clopidogrel
75 mg daily for 1 month.
2.2 | Techniques/methods
In short, the coronary artery can be exposed to radiation by means of
radioactive stents or catheter-based systems. Several isotopes with
different radiation particles can be used during radiation therapy. This
study will focus on the 32P β-emitting radioactive stents (RS) and
intracoronary β radiation brachytherapy (IRBT).20 In the original IRBT
studies, both the centered (Guidant) as noncentered (Novoste)
devices were used.
2.3 | Quantitative coronary angiography
Coronary angiography was performed after intracoronary administra-
tion of nitrates. The off-line analysis of at least two orthogonal projec-
tions was performed by means of the CAAS II (Cardiovascular
Angiographical Analysis System) (Pie Medical B.V., Maastricht, The
Netherlands).8,17 Edge restenosis was defined as >50% diameter ste-
nosis at follow-up, located within 5 mm proximal and/or distal to the
stent. Target vessel stenosis was defined as >50% diameter stenosis
at follow-up, located on any segment of the treated vessel.
2.4 | Follow-up
In 2015, survival status of all patients was retrieved from the Munici-
pal Civil Registry. Questionnaires were sent to all living patients focus-
ing on the occurrence of major adverse cardiac events (MACE). In
case of events reported, events were retrieved from medical records
in the hospitals. Two cardiologists adjudicated these events by using a
predefined classification form. In all RS studies, follow-up angiography
was performed at 6 months and 1 year as mandated by the protocol;
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a follow-up angiography in RS patients with a target lesion revascular-
ization at 6 months was not performed again at 1 year. In the IRBT
patients, control angiography was performed at 6 or 8 months,
depending on the study. In the control group, no routine angiographic
follow-up was performed.
2.5 | Study endpoints and definitions
Endpoints were: all-cause mortality and the patient oriented compos-
ite endpoint of major adverse cardiac events (MACE) which included
all-cause mortality, any myocardial infarction (MI) and any repeat
revascularization.
Repeat revascularization was defined as any PCI or CABG during
follow-up. Target lesion revascularization (TLR) was defined as any
surgical or percutaneous reintervention due to restenosis within the
stent or in the 5 mm proximal or distal peristent segments (edge reste-
nosis). Target vessel revascularization was defined as any
reintervention driven by lesions located in the treated vessel. Total
occlusion was defined as stent occlusion documented by coronary
angiography.
2.6 | Statistical analysis
Propensity score methodology was used to identify comparable
patients who were treated with standard routine PCI. The propensity
score was initially proposed by Rosenbaum and Rubin and has been
used in prior observational studies to help adjust for treatment selec-
tion bias.21 First, a propensity score for each patient was constructed,
providing an estimate of the propensity toward belonging to one
treatment group versus the other. This was done by using a multivari-
able logistic regression model with the type of intervention (standard
routine treatment coded as 0, IRBT as 1) as the dependent variable.
The following variables were entered into the model as independent
variables: age, gender, diabetes mellitus, hypertension, smoking, prior
MI, prior CABG, prior PCI, multivessel disease, impaired left ventricu-
lar function (ejection fraction <40%), and clinical presentation. Second,
each IRBT patient was matched with two control patients with identi-
cal propensity score by four decimals.16 The baseline characteristics
of the cohort before matching were as follows; mean age 59 years,
73% male, 25% history of PCI, 10% diabetes mellitus, 27% hyperten-
sion, and 26% smoking.
Categorical variables (presented as counts and percentages) were
compared between groups using the chi-square test or Fisher's exact
test and continuous variables (presented as their mean ± SD) were
compared using the Student's t test. Survival and event-free survival
rates were estimated by Kaplan–Meier curves and differences
between groups were assessed with the use of the log-rank test. Uni-
variate and multivariate Cox regression analyses were performed to
assess the associations between RS/IRBT and mortality or MACE and
to investigate an effect of a learning curve. Furthermore, multivariate
Cox regression and Kaplan–Meier curves were used for a landmark
analysis to investigate the association between RS/IRBT and MACE
beyond 2 years of follow-up. The following variables were entered
into the model: radiation therapy treatment (RS or IRBT), age, indica-
tion for PCI, gender, prior MI, prior PCI, prior CABG, extent of vessel
disease, left ventricular ejection fraction, smoking, hypertension, and
diabetes mellitus. Hazard ratios (HR) are presented with their 95%
confidence intervals (CI). Statistical significance of all tests was
defined at the p < .05 level. The SPSS statistical software package
(version 21.0 for Windows, SPSS Inc. Chicago, IL) was used for the
analysis.
3 | RESULTS
3.1 | Baseline characteristics
Mean age of the RS patients and IRBT patients was 59 years. In the
RS group, 26% were female, compared to 29% in the IRBT group
(Table 1). Baseline characteristics of treatment and control groups
were comparable, although IRBT patients more often had a history of
previous PCI (IRBT 52% versus control 41%, p < .01) and were more
often treated for restenosis (IRBT 41% versus control 26%, p < .001).
Median follow-up time was 17 years. Complete follow-up regarding
overall survival was achieved in 97% and the response rate of the
questionnaires was 84%. The missing information on overall survival
was caused by migration of patients.
3.2 | Radioactive stents
The cumulative survival at 5, 10, 15, and 17 years in the RS group was
92%, 84%, 73%, and 60%, respectively and 91%, 80%, 68%, and 65%,
respectively in the control group (Log rank p = .45) (Figure 1). After
adjustment, the hazard ratio for RS associated all-cause mortality was
0.92, 95% CI 0.63–1.34 (Table 2).
The cumulative MACE-free survival at 1, 5, 10, 15, and 17 years
in the RS group was 68%, 53%, 42%, 27%, and 20%, respectively and
84%, 72%, 54%, 40%, and 36%, respectively in the control group (Log
rank p = .0013) (Figure 1). Radioactive stents were associated with a
higher MACE rate at 17 years (adjusted HR 1.55, 95% CI 1.20–2.00).
Hazard ratios concerning TVR and MI are shown in Table 2.
3.3 | Intracoronary β radiation brachytherapy
The cumulative survival at 5, 10, 15, and 17 years in the IRBT group
was 90%, 80%, 69%, and 64%, respectively and 92%, 80%, 65%, and
58%, respectively in the control group (Figure 2). The difference in
mortality was not significant (Log rank p = .34). After adjustment, the
hazard ratio for IRBT associated all-cause mortality was 0.95, 95% CI
0.74–1.21 (Table 2).
The cumulative MACE-free survival at 1, 5, 10, 15, and 17 years
in the IRBT group was 70%, 47%, 34%, 25%, and 24%, respectively
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and 79%, 67%, 52%, 37%, and 30%, respectively in the control group
(Log rank p < .001) (Figure 2). After adjustment, IRBT was associated
with a higher MACE rate in comparison to the control group, HR 1.41,
95% CI 1.18–1.67 (Table 2). Whereas in the RS cohort MACE rates
were mainly driven by coronary revascularizations, MACE rates in the
IRBT cohort were driven by a higher revascularization rate as well as a
higher MI rate (adjusted HR 1.54, 95% CI 1.09–2.19). Hazard ratios
concerning the other endpoints are shown in Table 2.
When studying the Kaplan–Meier curve for the MACE-free sur-
vival of the IRBT cohort, three phases can be distinguished (Figure 2).
First of all there is an early sharp decrease in the IRBT group, where
after the curves run parallel until 10 years of follow-up. After
10 years, the curves seem to converge. In phase 1 (0–2 years), MACE
in the IRBT group (n = 122) and control group (n = 157) was predomi-
nantly driven by revascularizations (79% and 78%, respectively),
followed by MI (16% and 9%, respectively) and mortality (5% and
12%, respectively). In phase 2 (2–8 years), MACE in the IRBT group
(n = 66) was mainly driven by revascularizations (64%), followed by MI
(18%) and mortality (18%), while in the control group MACE (n = 97)
was driven by revascularizations (44%) and mortality (43%), followed
MI (12%). In phase 3 (8–17 years), MACE in the IRBT group (n = 39)
was driven by mortality (46%) and revascularizations (41%), followed
TABLE 1 Baseline characteristics
RS
group (n = 133)
Propensity matched control
group (n = 266)
p-
value
IRBT
group (n = 301)
Propensity matched control
group (n = 602)
p-
value
Sociodemographic
characteristics
Age 58.6 (±10.8) 59.1 (±10.8) .66 59.1 (±10.3) 59.4 (±11.0) .53
Female gender (%) 35 (26.3) 68 (25.6) .87 86 (28.6) 161 (26.7) .56
Risk factors
Diabetes mellitus
(%)
13 (9.8) 32 (12) .50 46 (16) 78 (13) .33
Hypertension (%) 47 (35.3) 101 (38) .61 94 (31.2) 180 (29.9) .67
Smoking (%) 32 (24.1) 58 (21.8) .61 57 (18.9) 129 (21.4) .40
Cardiac history
Previous MI (%) 60 (45.1) 110 (41.4) .47 101 (33.6) 204 (33.9) .87
Previous PCI (%) 18 (13.5) 47 (17.7) .29 156 (51.8) 247 (41.0) <.01
Previous CABG (%) 4 (3) 11 (4.1) .59 53 (17.6) 95 (15.8) .52
Extent of vessel
disease
.29 .66
1 95 (71.4%) 197 (74.1%) 173 (57.5%) 349 (58.0%)
2 32 (24.1%) 51 (19.2%) 78 (25.9%) 156 (25.9%)
3 5 (4.5%) 18 (6.8%) 50 (16.6%) 97 (16.1%)
Indication for PCI .67 .8
Unstable angina 58 (43.6) 122 (45.9) 92 (30.6) 195 (32.4)
Stable angina 75 (56.4) 144 (54.1) 207 (68.8) 407 (67.6)
Ejection fraction .22 .36
Normal (>50%) 112/127 (88.2%) 215/232 (92.7%) 239/292 (81.8%) 448/486 (92.2%)
Moderate (35–50%) 14/127 (11.0%) 14/232 (6.0%) 44/292 (15.1%) 32/486 (6.6%)
Poor (<35%) 1/127 (0.8%) 3/232 (1.3%) 9/292 (3.1%) 6/486 (1.2%)
Vessels treated .67 .1
Left anterior
descending
60 (45.1%) 124 (46.6%) 116 (38.5%) 242 (40.2%)
Right coronary
artery
45 (33.8%) 79 (29.7%) 106 (35.2%) 167 (27.7%)
Left circumflex 28 (21.1%) 63 (23.7%) 52 (17.3%) 144 (23.9%)
Left main – – 4 (1.3%) 9 (1.5%)
Saphenous vein
graft
– – 20 (6.6%) 30 (4.9%)
Abbreviations: CABG, coronary artery bypass graft; IRBT, intracoronary radiation brachytherapy; MI, myocardial infarction; PCI, percutaneous coronary
intervention; RS, radioactive stents.
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F IGURE 1 Kaplan–Meier survival curves for the radioactive stents (RS) versus control for all-cause mortality and major adverse cardiac
events (MACE) [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Hazard ratios radioactive stents cohort and intracoronary beta radiation brachytherapy cohort
RS cohort IRBT cohort
Event Unadjusted HR (95% CI) Adjusted HRa (95% CI) Unadjusted HR (95% CI) Adjusted HRa (95% CI)
Death from any cause 0.86 (0.59–1.24) 0.92 (0.63–1.34) 0.88 (0.69–1.12) 0.95 (0.74–1.21)
MACE 1.49 (1.16–1.91) 1.55 (1.20–2.00) 1.48 (1.26–1.75) 1.41 (1.18–1.67)
TVR 1.78 (1.31–2.41) 1.92 (1.40–2.62) 1.87 (1.54–2.28) 1.73 (1.42–2.12)
MI 1.32 (0.75–2.33) 1.39 (0.78–2.50) 1.58 (1.12–2.21) 1.54 (1.09–2.19)
Death or MI 1.03 (0.75–1.41) 1.08 (0.78–1.49) 1.01 (0.82–1.24) 1.07 (0.86–1.32)
Abbreviations: IRBT, intracoronary beta radiation brachytherapy; MACE, major cardiac events; MI, myocardial infarction; RS, radioactive stents; TVR,
target vessel revascularization.
aThe following variables were entered into the model: age, gender, prior MI, prior PCI, prior CABG, extent of vessel disease, left ventricular ejection
fraction, indication for PCI, smoking, hypertension and diabetes mellitus.
F IGURE 2 Kaplan–Meier survival curves for intracoronary beta radiation brachytherapy (IRBT) versus control for all-cause mortality and
major adverse cardiac events (MACE) [Color figure can be viewed at wileyonlinelibrary.com]
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by MI (13%), while in the control group MACE (n = 131) was mainly
driven by mortality (57%), followed by revascularizations (26%) and
MI (17%). Revascularizations in the IRBT patients were predominantly
classified as TLR.
3.4 | Landmark analyses beyond 2 years
Additional landmark analyses were performed to explore the differ-
ence in MACE rates between radiation therapy and control groups
beyond 2 years of follow-up. In the RS cohort, there were no differ-
ences in MACE-free survival (Figure 3, Log rank p = .22, adjusted HR
1.23, 95% CI 0.87–1.75).
In the IRBT group, the differences remained significant but were
less pronounced (Figure 3, Log rank p = .013, adjusted HR 1.35, 95%
CI 1.064–1.72).
3.5 | Angiographic characteristics during target
lesion revascularizations
To investigate the impact of edge restenosis on the revascularization
rate of radiation therapy patients, angiography images from our center
were analyzed. Of the 133 RS patients, 56 (42%) underwent at least
one TLR in our center (either surgical or percutaneous), resulting in a
total of 73 analyzed TLR's. Within the first year after RS implantation,
edge restenosis was responsible for an intervention in 20% (n = 27) of
the patients and for 29 lesions (71% of all lesions within the first year).
During the complete follow-up period, edge restenosis was responsi-
ble for an intervention in 29% (n = 38) of the patients and for
43 lesions (59%).
Of the 171 IRBT patients, 77 underwent at least one TLR in our
center, resulting in a total of 107 analyzed TLR's. Within the first year
after IRBT, edge restenosis was responsible for an intervention in 5%
(n = 9) of the patients and for 10 lesions (25%). During the complete
follow-up period, edge restenosis was responsible for an intervention
in 14% (n = 24) of the patients and for 26 lesions (24%). Total occlu-
sion occurred in 34 of the 107 TLR's (32%).
3.6 | Effect of a learning curve
Two analyses were performed to investigate an effect of the learning
curve during the IRBT period. First, the five-year period of IRBT treat-
ment was divided into two periods by using January first 2000 as cut-
off point. Cox proportional hazards analyses with occurrence of
MACE as outcome resulted in a univariate HR of 0.91 (95% CI
0.69–1.19) and a multivariate HR of 0.84 (95% CI 0.62–1.13). Second,
the last 2 years of IRBT treatment were tested against the first
2 years. This resulted in a univariate HR of 1.0 (95% CI 0.72–1.39)
and a multivariate HR of 0.84 (0.57–1.12).
4 | DISCUSSION
This study evaluated the very late (17 years) clinical outcome of both
radioactive stents and intracoronary β radiation brachytherapy as
compared with matched control groups treated with routine PCI dur-
ing the same time period in our center. The main findings were (a) in
the very long-term, there were no survival differences between the
treatment group and controls, (b) the excess in MACE as reported pre-
viously in the treatment group at 6 months and 12 months is not per-
sistent: beyond the second year, the difference in MACE rates
decreased, and (c) interestingly, the event rates in the IRBT group
started to decrease in comparison to the control group after 10 years,
resulting in a comparable clinical outcome in the very long-term.
F IGURE 3 Landmark analyses for radioactive stents (RS) and intracoronary beta radiation brachytherapy (IRBT) versus control for major
adverse cardiac events (MACE) [Color figure can be viewed at wileyonlinelibrary.com]
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4.1 | Radioactive stents versus intracoronary β
radiation brachytherapy
Radioactive stents were implanted in one quarter of our radiation
therapy group, while the remaining patients underwent IRBT. Inter-
estingly, in both groups the same patterns were observed with
respect to all-cause mortality and MACE. The landmark analyses
showed that the first 2 years of follow-up account for a significant
part of the observed difference in MACE rates. In fact, beyond
2 years, there no longer were differences between RS and control
patients. Furthermore, in the IRBT cohort, the differences in MACE
rates decreased after moving the baseline to 2 years after
treatment.
In both treatment groups, MACE was predominantly driven
by TLR within the first 2 years after treatment. Our angiographic
analysis showed that approximately 30% of the RS patients and
15% of the IRBT patients had a TLR because of the edge effect.
In the IRBT patients, stent thrombosis was responsible for 32%
of the TLR's.
In the IRBT cohort, MACE rates were also driven by a higher MI
rate. However, the important question is whether the higher MI rate
is a true phenomenon or the result of information bias. Events were
initially reported through questionnaires where after medical records
were obtained to confirm self-reported events. Between-group differ-
ences in this self-reporting may have accounted for a part of the
observed differences.
4.2 | Intracoronary radiation therapy—persistent
failure?
When studying the Kaplan–Meier curve for MACE-free survival of
the IRBT cohort (Figure 2), there is a sharp decrease in the IRBT
group during the first 2 years of follow-up. Eventually, the differ-
ence in MACE rates decreased over time. These data with most
radiation failure occurring within the first two years, might suggest
rather the aftermath of technical shortcomings in the baseline pro-
cedure (with geographical miss) than a deleterious effect of radia-
tion itself. This is important, as in the past both, potentially
beneficial radiation effects such as hormesis and potentially
adverse radiation effects such as media fibrosis of the epi- and
endocardial vessels have been described. Fortunately, there was no
MACE excess at the long-term outcome.22,23 Additional analyses
showed no effect of a learning curve.
It is not clear why this effect seems to be more pronounced in
the IRBT group as compared to the RS group. A possible explana-
tion could be the different vascular response to short (IRBT) versus
prolonged (RS) after loading as observed in the past. Radioactive
stents have been associated with inward vessel remodeling,
whereas IRBT was associated with outward vessel remodeling with
an increase in plaque and total vessel volume at 6 months.24,25
However, there are no data elucidating the relevance of these
effects in the very long run.
4.3 | Role of coronary radiation therapy in daily
clinical practice—cure for restenosis?
To the best of our knowledge, this is the first study presenting the
results of both radioactive stents and intracoronary β radiation ther-
apy after more than 10 years of follow-up. Because of the poor short-
and intermediate-term results of radioactive stents, they have been
discarded as an option in the treatment of coronary artery disease.
However, there are some highly specialized centers where catheter
based brachytherapy is still being performed. RS have never been
tested against drug eluting stents (DES) in a clinical trial, but IRBT has
been tested.
The SISR trial compared sirolimus-eluting stents (SES) to vascular
brachytherapy for in-stent restenosis within bare metal stents. After
3 years of follow-up, SES were associated with a better TLR- and
TVR-free survival.26 The TAXUS V ISR trial randomized patients
between a paclitaxel-eluting stent (PES) and vascular brachytherapy
as treatment for bare metal stent restenosis.27 At 2 year follow-up,
the PES subgroup suffered less from clinical restenosis and therefore
MACE and TVF appeared to be in favor of PES. The paclitaxel- and
sirolimus-eluting stents that were used in the previously mentioned
trials are early-generation DES. Use of these stents has drastically
decreased since the availability of new-generation DES. Recent guide-
lines by the European Society of Cardiology state that new-generation
DES are recommended over BMS in non-ST-segment elevation acute
coronary syndromes (NSTE-ACS).28 Furthermore, their guidelines sug-
gest that new-generation DES are more effective and potentially safer
than BMS during primary PCI in patients presenting with ST-segment-
elevation myocardial infarction (STEMI).29 New-generation DES have
drastically reduced the incidence of restenosis since the BMS era, but
they still suffer from a restenosis rate of approximately 10–15%.1
Therefore, the focus should be on preventing restenosis of the new-
generation DES.
There are a number of possible treatment options such as res-
tenting with a DES, angioplasty with (drug-coated) balloons and coro-
nary surgery. Although each patient requires a tailored approach
based on the location and extent of restenotic tissue, the presence of
additional lesions and comorbidity, restenting with DES or the use of
drug coated balloons, which are currently not available in the United
States, seem to be among the best choices.30–32
4.4 | Limitations
Some limitations need to be acknowledged. First, the study was not
randomized, which is generally preferred when comparing treatments.
Because of the study design, potential validity issues need to be
addressed. First of all, confounding might have biased the results. By
using propensity scores, both groups were evenly matched with
regard to the patient characteristics, except for previous PCI and
restenosis, which were more prevalent in the IRBT group. Further-
more, multivariable analyses were performed to adjust for possible
confounders. However, residual confounding might still have
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influenced the results. Second, patients from both the radioactive
stent- as well as the IRBT cohort were part of different trials with vari-
ability in terms of the applied technology and medication. At last, the
coronary radiation patients were part of different studies whose pro-
tocols mandated angiographic control after 6 and/or 12 months. Thus,
information bias has affected the short- and intermediate-term results
and therefore caution is urged when reviewing the early results.
5 | CONCLUSION
Coronary radiation therapy was associated with a relatively high fail-
ure rate within the first year. However, the difference in MACE rates
decreased beyond 2 years, resulting in a comparable long-term clinical
outcome. Importantly, no excess in mortality was observed.
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